Mizuho Initiates Coverage of Myriad Genetics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Mizuho initiated coverage of Myriad Genetics on Thursday, calling the Salt Lake City firm "the crown jewel in personalized medicine."

In a report, analyst Peter Lawson initiated coverage with an "outperform" rating and a 12-month target share price of $25, or about 22 percent above the current stock price.

On Thursday, Myriad shares closed at $20.83.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.